COMP <GO>
PTGX vs MDGL // FREE CASH FLOW YIELD
Protagonist Therapeutics Inc. (NASDAQ) VS. Madrigal Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: PTGX 6
— MDGL 4
▲ FREE CASH FLOW YIELD LEADER: PTGX
LAST: $139.37 (-3.78%) • MKT CAP: $9.02B
fcf-yield
0.60%
LAST: $431.16 (+0.19%) • MKT CAP: $9.96B
fcf-yield
-1.91%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTGX VS. MDGL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTGX | MDGL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.70% | -29.70% | +13.00 | PTGX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 0.60% | -1.91% | +2.51 | PTGX | /fcf-yield <GO> |
| Operating Margin | -6.00% | -31.30% | +25.30 | PTGX | /operating-margins <GO> |
| Net Profit Margin | -5.00% | -30.10% | +25.10 | PTGX | /net-margins <GO> |
| Revenue Growth (YoY) | 0.00% | 180.00% | -180.00 | MDGL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 7.65 | +18.35 | PTGX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 6/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.3 | 30.8 | +15.50 | PTGX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.08 | -0.09 | MDGL | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 24.0x | +7.00 | MDGL | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.02B | $9.96B | -$943.1M | MDGL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTGX REV | MDGL REV | PTGX GROSS % | MDGL GROSS % | PTGX FCF | MDGL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $442.8M | $958.4M | — | — | $56.1M | -$190.0M |
| FY 2024 | $708.0M | $180.1M | — | 96.5% | $182.8M | -$457.0M |
| FY 2023 | $262.2M | $1.07B | — | — | -$70.2M | -$324.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTGX // BETA 0.99
MDGL // BETA 1.08